Home » Stocks » Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. (BLCM)

Stock Price: $6.93 USD -0.11 (-1.56%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 35.06M
Revenue (ttm) 5.24M
Net Income (ttm) -86.63M
Shares Out 5.06M
EPS (ttm) -17.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $6.93
Previous Close $7.04
Change ($) -0.11
Change (%) -1.56%
Day's Open 7.04
Day's Range 6.76 - 7.07
Day's Volume 20,435
52-Week Range 3.32 - 27.90

More Stats

Market Cap 35.06M
Enterprise Value n/a
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 5.06M
Float 5.03M
EPS (basic) -20.07
EPS (diluted) -17.50
FCF / Share -9.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 428,183
Short Ratio 8.88
Short % of Float 8.07%
Beta 2.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.70
PB Ratio 40.34
Revenue 5.24M
Operating Income -67.48M
Net Income -86.63M
Free Cash Flow -47.28M
Net Cash 38.29M
Net Cash / Share 7.57
Gross Margin -1,056.68%
Operating Margin -1,288.67%
Profit Margin -1,885.30%
FCF Margin -903.02%
ROA -50.42%
ROE -6,120.17%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(150.07% upside)
Current: $6.93
Target: 17.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth537.77%505.41%-52.32%37.59%-84.16%-8.29%32.01%-
Gross Profit7.
Operating Income-87.36-95.47-87.39-68.38-49.14-57.84-7.92-6.27
Net Income-112-98.04-91.78-69.24-48.55-83.97-7.97-6.26
Shares Outstanding4.684.023.172.702.630.250.180.16
Earnings Per Share-24.01-24.37-28.90-25.70-18.40-340.40-50.50-42.60
Operating Cash Flow-77.57-74.78-72.98-50.44-35.73-57.31-7.61-7.74
Capital Expenditures-0.52-1.62-12.10-7.22-5.42-0.80-0.37-2.05
Free Cash Flow-78.09-76.40-85.08-57.66-41.15-58.11-7.98-9.79
Cash & Equivalents93.8293.0010511394.0619211.171.63
Total Debt38.0435.9635.1120.390.13-0.800.45
Net Cash / Debt55.7857.0469.9893.0393.9319210.371.18
Book Value-26.2268.4884.6596.57152192-28.15-19.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bellicum Pharmaceuticals, Inc.
Country United States
Employees 107
CEO Richard A. Fair

Stock Information

Ticker Symbol BLCM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BLCM
IPO Date December 18, 2014


Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.